Press Releases

Press Releases

Press Releases

Date Title and Summary Additional Formats
Dec 10, 2018
Multiple Oncotype DX Study Presentations at the 2018 San Antonio Breast Cancer Symposium Reinforce Real-world Value of the Oncotype DX Breast Recurrence Score® Test in Patients Regardless of Age or Race
REDWOOD CITY, Calif. , Dec. 10, 2018 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced results from multiple Oncotype DX Breast Recurrence Score ® (RS) presentations at the 2018 San Antonio Breast Cancer Symposium ® (SABCS), reinforcing the value of the Oncotype DX ® test in
Dec 03, 2018
Genomic Health and Biocartis Expand Collaboration to Urology with the Development of an Idylla™ Oncotype DX® Genomic Prostate Score® Test
REDWOOD CITY, Calif. and MECHELEN, Belgium , Dec. 3, 2018 /PRNewswire/ --  Genomic Health , Inc. (NASDAQ: GHDX), the world's leading provider of genomic-based diagnostic tests and Biocartis Group NV, an innovative molecular diagnostics company (Euronext Brussels: BCART), today announced they have
Nov 29, 2018
New Analysis of NSABP Randomized B-20 Study Confirms Patients with Oncotype DX Breast Recurrence Score® Results Greater Than 25 Have Life-saving Substantial Benefit from Chemotherapy, Reinforcing the Conclusions of the Landmark TAILORx Study
Published Results Underscore Value of Oncotype DX® Test in Identifying Women with Early-stage Breast Cancer Who May Receive Life-saving Benefit from Chemotherapy REDWOOD CITY, Calif. , Nov. 29, 2018 /PRNewswire/ -- Genomic Health , Inc.  (NASDAQ: GHDX)  and the NSABP Foundation today announced the
Nov 19, 2018
Genomic Health Announces Presentation of Two Large Studies at the 2018 San Antonio Breast Cancer Symposium, Reinforcing Real-world Value of the Oncotype DX Breast Recurrence Score® Test
REDWOOD CITY, Calif. , Nov. 19, 2018 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that it will present results from two large studies of the Oncotype DX Breast Recurrence Score ® test at the 2018 San Antonio Breast Cancer Symposium ® (SABCS), which will be held December 4-8 .
Nov 08, 2018
Genomic Health to Present at the 2018 Canaccord Genuity Medical Technologies & Diagnostics Forum
REDWOOD CITY, Calif. , Nov. 8, 2018 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that it will present at the 2018 Canaccord Genuity Medical Technologies and Diagnostics Forum in New York City on Thursday, November 15, 2018 at 9:30 a.m. Eastern Time .
Nov 06, 2018
Genomic Health Announces Record Revenue and Profit in Third Quarter 2018 Financial Results; Raises Full Year Guidance
REDWOOD CITY, Calif. , Nov. 6, 2018 /PRNewswire/ -- Genomic Health , Inc. (NASDAQ: GHDX) today reported financial results and business progress for the quarter ended September 30, 2018 . "We continue to deliver record results in 2018, including 23 percent revenue growth and $12 million in profit
Oct 30, 2018
Genomic Health to Announce Third Quarter 2018 Financial Results and Host Conference Call on Tuesday, November 6, 2018
REDWOOD CITY, Calif. , Oct. 30, 2018 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ:  GHDX) today announced that the company will host a conference call and webcast on Tuesday, November 6 at 4:30 p.m. Eastern Time to discuss its third quarter 2018 financial results.
Oct 29, 2018
Medicare Establishes Final Local Coverage Determination (LCD) for Use of the Oncotype DX® AR-V7 Nucleus Detect™ Test in Patients with Metastatic Castrate Resistant Prostate Cancer Effective December 10
Medicare coverage supports clinical utility of the Oncotype DX AR-V7 Nucleus Detect test, providing 25,000 Medicare patients with coverage SAN DIEGO and REDWOOD CITY, Calif. , Oct. 29, 2018 /PRNewswire/ --  Epic Sciences, Inc. (Epic) and Genomic Health, Inc.
Oct 22, 2018
Genomic Health Announces Multiple Studies Reinforcing Value of Oncotype DX® Tests in Guiding Treatment for Breast and Prostate Cancer Patients
Studies Presented at ESMO 2018 Congress Underscore Growing Clinical Evidence Across Genomic Health's Test Portfolio REDWOOD CITY, Calif. , Oct. 22, 2018 /PRNewswire/ --  Genomic Health , Inc. (Nasdaq: GHDX) today announced results from multiple studies of its Oncotype DX ® tests highlighting their
Sep 28, 2018
New Published Data and Recent Positive Private Payor Coverage Decisions Underscore Value and Utility of the Oncotype DX Genomic Prostate Score® (GPS™) Test
New Analysis from Unprecedented Study of Patient Medical Records from Large Private U.S. Health Insurer Reconfirms Active Surveillance Increases by 30 Percent in Patients Using GPS™ Test, Improving Adherence to Guideline-based Treatment New Publication Showing Test's Value Independent of MRI and